Posaconazole is a potent, broad-spectrum triazole antifungal agent currently in clinical
development for the treatment of refractory invasive fungal infections. Eight healthy male subjects …

Parenteral naloxone has been approved to treat opiate overdose for over 4 decades. Intranasal
naloxone, administered “off label” using improvised devices, has been widely used by …

DOV 216,303 [(±)‐1‐(3,4‐dichlorophenyl)‐3‐azabicyclo‐[3.1.0]hexane hydrochloride] is the
prototype of a class of compounds referred to as “triple” reuptake inhibitors. Such …

The dramatic rise in overdose deaths linked to synthetic opioids (eg, fentanyl, carfentanil)
may require more potent, longer-duration opiate antagonists than naloxone. Both the high …

Bicifadine (1-p-tolyl-3-azabicyclo[3.1.0]hexane) inhibits monoamine neurotransmitter uptake
by recombinant human transporters in vitro with a relative potency of norepinephrine > …

For more than a decade, first responders and the general public have been able to treat
suspected opioid overdoses using an improvised nasal naloxone device (INND) constructed …

Rats and guinea pigs dosed with dl-6-chlorotryptophan or d-6-chlorotryptophan excrete
significantly greater amounts of 3-hydroxyanthranilic acid in the urine than do animals treated …

Carboxyalkyl peptides containing a biphenylylethyl group at the P 1 ‘ position were found to
be potent inhibitors of stromelysin-1 (MMP-3) and gelatinase A (MMP-2), in the range of 10−…

This report describes the first evaluation in humans of DOV 216,303, a putative antidepressive
that inhibits the reuptake of norepinephrine, serotonin, and dopamine. Subjects received …

Replacing one amide bond in macrocyclic renin inhibitors of the general structure 1 and 2
with an ester linkage gave glutamate-derived inhibitors 3 and serine-derived inhibitors 4. …